Clinical Trials on Cyclophosphamide

Total 12 results

Fundació Institut de Recerca de l'Hospital de la...

Recruiting

Influence of Timing PTCy in AlloSCT

Cyclophosphamide Toxicity | Allogenic Haematopoetic Transplantation

Spain
Taizhou Hospital

Unknown

Paclitaxol Every 2 Week Versus Paclitaxol Every 1 Week in the Adjuvant Treatment of Breast Cancer (PATEN)

Breast Cancer | Paclitaxel | Cyclophosphamide | Epirubicin
National Cancer Institute (NCI)
Cancer and Leukemia Group B

Completed

Phase III Comparison of Adjuvant Chemotherapy W/High-Dose Cyclophosphamide Plus Doxorubicin (AC) vs Sequential Doxorubicin Fol by Cyclophosphamide (A-C) in High Risk Breast Cancer Patients With 0-3 Positive Nodes (Intergroup, CALGB 9394)

Breast Cancer | High Risk | Cyclophosphamide | Positive Nodes | Doxorubicin

United States
Qianfoshan Hospital

Not yet recruiting

Study on the Application of Hyperspectral Imaging Technique in CTX Treatment of IMN

Idiopathic Membranous Nephropathy | Cyclophosphamide | Hyperspectral Imaging
National Research Center for Hematology, Russia

Not yet recruiting

Comparison of PT-Cy at a Dose of 25 mg/kg/Day and PT-Cy at a Dose of 50 mg/kg/Day in GVHD Prophylaxis (CY25)

Hematologic Malignancy | Graft Versus Host Disease | Cyclophosphamide Adverse Reaction
Second Xiangya Hospital of Central South University
Peking Union Medical College Hospital; The Second Hospital of Hebei Medical... and other collaborators

Recruiting

MMF Versus CYC in the Induction Therapy of Pediatric Active Proliferative LN (MyCITS)

Lupus Nephritis | Mycophenolate Mofetil | Cyclophosphamide

China
Chitwan Medical College

Completed

Cyclophosphamide Versus Mycophenolate Mofetil in Lupus Nephritis

To Compare the Effects of Mycophenolate Mofetil With Cyclophosphamide in Neplaese Lupus Nephritis Patients
UMC Utrecht
Boehringer Ingelheim; ZonMw: The Netherlands Organisation for Health Research... and other collaborators

Recruiting

Upfront Autologous HSCT Versus Immunosuppression in Early Diffuse Cutaneous Systemic Sclerosis (UPSIDE)

Systemic Sclerosis | Scleroderma, Diffuse | Mycophenolate Mofetil | Scleroderma | Autologous Stem Cell Transplantation | Cyclophosphamide | Systemic Scleroses, Diffuse | Treatment Strategy

Italy, Switzerland, Netherlands, Sweden, United Kingdom
Kai Mu

Recruiting

Early Identification and Evaluation of Cyclophosphamide Cardiotoxicity (EIECC)

Cardiotoxicity | Hematopoietic Stem Cell Transplantation | Echocardiography | Cyclophosphamide | Cardio-oncology

China
Second Affiliated Hospital of Soochow University

Unknown

Combination of G-CSF, Bortezomib, Cyclophosphamide and Dexamethasone in Patients With Multiple Myeloma

Myeloma | Dexamethasone | Granulocyte Colony-Stimulating Factor | Cyclophosphamide | Bortezomib

China
Fudan University

Unknown

Chidamide Combined With R-GDP in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)

Neoplasms | Immune System Diseases | Lymphoma, B-Cell | Lymphoma, Large B-Cell, Diffuse | Lymphoproliferative Disorders | Lymphatic Diseases | Immunoproliferative Disorders | Lymphoma, Non-Hodgkin | Gemcitabine | Cisplatin | Dexamethasone | Rituximab | Cyclophosphamide | Chidamide | Neoplasm by Histology | HDAC Inhibitor

China
Celularity Incorporated

Terminated

Natural Killer Cell (CYNK-001) IV Infusion or IT Administration in Adults With Recurrent GBM (CYNK001GBM01)

Glioblastoma Multiforme | Molecular Mechanisms of Pharmacological Action | Giant Cell Glioblastoma | Astrocytoma, Grade IV | Physiological Effects of Drugs | Peripheral Nervous System Agents | Analgesics | Analgesics, Non-narcotic | Cyclophosphamide | Immunosuppressive Agents | Immunologic Factors | Antiviral... and other conditions

United States

Clinical Trials on Cyclophosphamide

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Jamaica

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations